Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
1.840
+0.140 (8.24%)
At close: Oct 2, 2025, 4:00 PM EDT
1.880
+0.040 (2.17%)
After-hours: Oct 2, 2025, 7:51 PM EDT

Propanc Biopharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2016 - 2020
Selling, General & Admin
57.051.291.531.731.58
Upgrade
Research & Development
0.220.250.250.260.23
Upgrade
Operating Expenses
57.281.541.781.991.81
Upgrade
Operating Income
-57.28-1.54-1.78-1.99-1.81
Upgrade
Interest Expense
-0.56-0.67-0.53-0.57-0.45
Upgrade
Interest & Investment Income
0000.010
Upgrade
Currency Exchange Gain (Loss)
-0.090.020.01-0.040.03
Upgrade
Other Non Operating Income (Expenses)
-0.120.18-0.53-0.1-0.01
Upgrade
EBT Excluding Unusual Items
-58.05-2-2.83-2.7-2.24
Upgrade
Other Unusual Items
-0.870.050.04-0.020.1
Upgrade
Pretax Income
-58.92-1.95-2.79-2.71-2.14
Upgrade
Income Tax Expense
--0.13-0.13-0.05-0.11
Upgrade
Net Income
-58.92-1.82-2.66-2.66-2.03
Upgrade
Preferred Dividends & Other Adjustments
-0.190.470.70.39
Upgrade
Net Income to Common
-58.92-2.01-3.13-3.36-2.42
Upgrade
Shares Outstanding (Basic)
4----
Upgrade
Shares Outstanding (Diluted)
4----
Upgrade
EPS (Basic)
-14.85----
Upgrade
EPS (Diluted)
-14.85----
Upgrade
Free Cash Flow
-0.41-0.94-1.11-1.44-1.15
Upgrade
Free Cash Flow Per Share
-0.10----
Upgrade
EBITDA
-57.28-1.54-1.77-1.99-1.81
Upgrade
D&A For EBITDA
00000
Upgrade
EBIT
-57.28-1.54-1.78-1.99-1.81
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.